Scheduling status: S2

Proprietary Name and Dosage Form:

SUPIROBAN OINTMENT

glenmark

The Composition of the Medicine

The active ingredient (medicine) contained in Supiroban Ointment is mupirocin. 1 g of the ointment contains 20 mg of mupirocin.

Supiroban Ointment also contains the following inactive raw materials:

- Polyethylene Glycol 350
- Polyethylene Glycol 400

Indications and Use

What is Supiroban Ointment used for?

Supiroban Ointment is indicated for the topical treatment of primary and secondary skin infections.

Supiroban Ointment may be used to avoid bacterial contamination of small wounds, incisions and other clean lesions and to prevent infection of abrasions and small cuts and wounds.

Instructions before applying Supiroban Ointment

(i) Contraindications (Who should not use Supiroban Ointment)

Do not use Supiroban Ointment if you are allergic to mupirocin (the active ingredient in Supiroban Ointment), or to the inactive ingredients. Please refer above for a list of inactive ingredients.

Do not use Supiroban Ointment to treat skin lesions infected with a type of bacteria called *Pseudomonas aeruginosa.*

(ii) Precautions and (iii) Warnings

Tell your doctor about any prescription and non-prescription medicines you are using, including natural or herbal remedies. Tell your doctor if you:

- Ever had kidney problems
- Are pregnant or plan to become pregnant or are breast feeding your baby while using Supiroban Ointment, please consult your doctor, pharmacist or other health care professionals for advice.

Supiroban Ointment is not suitable for :

- Use in the eye
- Use in the nose
- Use in conjunction with cannulae

Supiroban Ointment should be used with caution in patients with extensive burns or wounds because of the possibility of macrogol toxicity i.e. toxicity due to one of the inactive ingredients of Supiroban Ointment.

(iv) Interactions

Do not mix Supiroban Ointment with other preparations as there is a risk of dilution, resulting in reduction in the antibacterial activity and potential loss of stability of Supiroban Ointment.

Do not start any new prescription or non-prescription medicines or supplements, unless you check with your doctor first.

If you are taking / using medicines on a regular basis, using Supiroban Ointment at the same time with another medicine may cause undesirable interactions. Please consult your doctor, pharmacist or other health care professionals for advice.

Instructions on how to use Supiroban Ointment

Apply to affected areas two to three times a day.

A small quantity of Supiroban Ointment should be applied to cover the affected area. The treated area may be covered by a dressing.

Do not share medicines prescribed for you with any other person.

Side effects

Supiroban Ointment may cause the following side effects:
Burning, stinging, dryness, skin irritations.

In the event of local irritation to the skin, treatment should be discontinued; the product should be rinsed off. Consult your doctor, pharmacist or other healthcare professionals for an appropriate alternative therapy for the infection.

Tell your doctor if you are concerned about any side effects you experience.

Not all side-effects reported for Supiroban Ointment are included in this leaflet. Should your general health worsen while using Supiroban Ointment, please consult your doctor, pharmacist or other health care professionals for advice.

Storage and disposal information

Store Supiroban Ointment at room temperature (at or below 25 ^{o}C).
Do not refrigerate.

STORE ALL MEDICINES OUT OF THE REACH OF CHILDREN.

Presentation

Supiroban Ointment is available in a latex, aluminium (not lacquered), collapsible tube with cap. The tube contains 14 g, 15 g, 30 g or 50 g ointment.

Identification

A white, translucent water miscible ointment.

Registration Number

A 43/20.1.6/0680

Namibia Reg. No. 11/20.1.6/0213

Name and Business address of the holder of the Certificate of Registration

Glenmark Pharmaceuticals South Africa (Pty) Ltd
Unit 7/8 York House
Tybalt Place, 185 Howick Close
Waterfall Office Park
Bekker Street
VORNA VALLEY

Date of Publication of the Package Insert
4 March 2011